Reddy Labs signed an agreement Citius Pharmaceuticals of the US to sell its rights to an anti-cancer agent. Reddy Labs will sell all of its rights to E7777 (an engineered IL-2-diphtheria toxin fusion protein) along with certain related assets to Citius Pharma of the US. Reddy Labs will be paid $40 million upfront with progress-based milestone payments of up to $70 million for additional approvals over a period of time.
It may be recollected that Reddy Labs had acquired the exclusive global rights to the anti-cancer agent E7777 from Eisai Co way back in 2016.
Reddy Labs signed an agreement Citius Pharmaceuticals of the US to sell its rights to an anti-cancer agent. Reddy Labs will sell all of its rights to E7777 (an engineered IL-2-diphtheria toxin fusion protein) along with certain related assets to Citius Pharma of the US. Reddy Labs will be paid $40 million upfront with progress-based milestone payments of up to $70 million for additional approvals over a period of time.
It may be recollected that Reddy Labs had acquired the exclusive global rights to the anti-cancer agent E7777 from Eisai Co way back in 2016.